BPC-157 and Wolverine Together: What Is Known
BPC-157 and Wolverine taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
- Rat Achilles tendon study of BPC-157, TB-500 and their combination (the components of the Wolverine blend). The combination gave no added benefit over either agent alone. Animal data only. · PMID 42542926
Side by side
Showing 9 of 12 fields where the two differ. Category, WADA, Half-life are the same or both unknown.
| Field | BPC-157 | Wolverine |
|---|---|---|
| Class | Gastric pentadecapeptide | BPC-157 + TB-500 blend |
| Also called | BPC, body protection compound, Pentadecapeptide BPC 157 | Wolverine stack, BPC-157 + TB-500 |
| Category | Healing & recovery | Healing & recovery |
| FDA status | PCAC voted 8–6 for 503A (Jul 2026) | Not FDA approved · unstudied blend |
| PCAC vote, Jul 2026 | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition. | Prohibited by WADA (S0)Contains BPC-157 (named in S0) and TB-500 (S2.3). A blend is prohibited if any component is. |
| Anti-doping detection |
|
|
| Half-life | less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 | BPC-157: less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 |
| Evidence strength | Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143 | Human RCT evidence, 4 of 4TB-500: Cardiovascular research 2025, PMID 41229390 |
| Human studies we summarised | 3 human (0 randomized or controlled) of 25 summarised | 10 human (7 randomized or controlled) of 41 summarised, across ingredients |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 10 mg, 20 mg |
What the single combination study found in rats
A rat study tested BPC-157, TB-500 and the pair after surgical Achilles tendon repair, with control, single-peptide and combination groups.[8]
Versus controls, the TB-500 group had significantly lower Bonar scores, and the TB-500 and combination groups had significantly lower Movin scores (tendon structure). The quoted results name no significant change for BPC-157 alone.[8]
In these rats, combining the two gave no additional benefit over either agent alone, according to the authors.[8]
The closest human report
In a knee-pain survey, 11 of the 12 patients who received BPC-157 alone reported significant improvement.[18]
The 4 patients who received BPC-157 with thymosin beta-4 (TB4) had 75% improvement, with the other 25% reporting no relief. Four patients is too few for a comparison.[18]
The review used no specific tools to measure function, quality of life, stiffness or activities of daily living.[18]
Regulatory and sport status
FDA's safety-risk note on BPC-157 cites immunogenicity risk and impurity complexities for compounded versions.[19]
FDA's advisory committee was due to discuss BPC-157 and TB-500 bulk substances, among others, for the 503A bulks list on July 23, 2026.[20]
WADA names TB-500 as a thymosin beta-4 derivative in its growth factor class.[2]
WADA's prohibited list names BPC-157 by name, in a class that also names DNP.[2]
Common questions
Is Wolverine just BPC-157 and TB-500?
On this page the stack means those two peptides. The only study that tested them together was in rats, and it found no added benefit.[8]
Is the Wolverine stack safe?
FDA says it has identified no, or only limited, safety information on BPC-157 for the proposed routes, and lacks the information to know whether it would cause harm in humans.[19]
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 4Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 5Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 6Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
- 7Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
- 8Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 9Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
- 10Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 11Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
- 12A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
- 13Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
- 14Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 15PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16Drugs@FDA (openFDA) search: active ingredient "BPC-157"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 17Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 18Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Alternative therapies in health and medicine · 2021PMID 34324435Accessed 2 Oct 2026
- 19Official web pageOfficial web page · web page
- 20Official web pageOfficial web page · web page
Found an error? Report a correction.